<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01901003</url>
  </required_header>
  <id_info>
    <org_study_id>2011-005171-16</org_study_id>
    <secondary_id>2011-32</secondary_id>
    <nct_id>NCT01901003</nct_id>
  </id_info>
  <brief_title>Sedative Premedication: Efficacy On Patient Experience</brief_title>
  <acronym>PremedX</acronym>
  <official_title>SEDATIVE PREMEDICATION: EFFICACY ON PATIENT EXPERIENCE</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique Hopitaux De Marseille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique Hopitaux De Marseille</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Seven French university hospitals will participate in this multicentric prospective, blinded&#xD;
      and randomized study. The investigators designed 3 study groups: Lorazepam 2.5mg, Placebo&#xD;
      (microcrystalline celluloses) and no premedication at all. The third group (no premedication)&#xD;
      is necessary in order to evaluate a placebo response, which may be significant on anxiety&#xD;
      level and patients perceptions of care. It was calculated that 969 patients had to be&#xD;
      included in order to obtain a 5 point difference between groups on the EVAN score with 80 %&#xD;
      statistical power, leading to the inclusion of 1200 patients with an estimated maximum&#xD;
      dropout rate of 15 %. All adults below 70 years and scheduled for elective surgery under&#xD;
      general anesthesia can be included after information by an anesthesiologist in charge of the&#xD;
      study and written informed consent. Non inclusion criterions are: a weight below 45 Kg, a&#xD;
      counter indication to benzodiazepine, surgeries that could impair cognitive functions&#xD;
      (cardiac or neurologic surgery), usual use of neuroleptics or lithium, drug addiction or&#xD;
      former cognitive disease. The technique of anesthesia will be decided by the attending&#xD;
      anesthesiologist, who will be unaware of the premedication technique, independently of the&#xD;
      study protocol.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Actual">June 2014</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the EVAN score</measure>
    <time_frame>2 years</time_frame>
    <description>to evaluate patient satisfaction of the perioperative period</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>the perioperative level of anxiety</measure>
    <time_frame>2 years</time_frame>
    <description>APAIS score (Moerman 1996) before surgery</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">1200</enrollment>
  <condition>Perioperative Anxiety</condition>
  <arm_group>
    <arm_group_label>placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>no premedication group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>no premedication</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lorazepam group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>lorazepam</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lorazepam</intervention_name>
    <arm_group_label>Lorazepam group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>no premedication</intervention_name>
    <arm_group_label>no premedication group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (microcrystalline celluloses)</intervention_name>
    <arm_group_label>placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  male or female aged 18 to 70 years or more;&#xD;
&#xD;
          -  About a weight greater than 45 kg;&#xD;
&#xD;
          -  Subject to benefit from a scheduled surgery under general anesthesia;&#xD;
&#xD;
          -  Topic respecting the ambivalence clause defined below:&#xD;
&#xD;
               1. Having no cons-indication to the use of benzodiazepines;&#xD;
&#xD;
               2. Having no known allergy to benzodiazepines;&#xD;
&#xD;
               3. May be a candidate for the prescription of premedication;&#xD;
&#xD;
          -  Topic able to complete a self-administered questionnaire;&#xD;
&#xD;
          -  Subject has signed a written informed consent and agreeing to abide by the&#xD;
             instructions of the Protocol&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  - Topic of over 70 years;&#xD;
&#xD;
          -  Topic 45 kg or less;&#xD;
&#xD;
          -  Topic demanding to receive anxiolytic premedication;&#xD;
&#xD;
          -  Subject severe respiratory insufficiency;&#xD;
&#xD;
          -  Topic minor, pregnant or breastfeeding, about not being affiliated to the social&#xD;
             security system;&#xD;
&#xD;
          -  Topic for which surgery is performed under local anesthesia;&#xD;
&#xD;
          -  Subject unable to perform only a self-administered questionnaire (inability to read&#xD;
             French, severe cognitive impairment);&#xD;
&#xD;
          -  Subject to which the scheduled surgery may cause postoperative cognitive dysfunction&#xD;
             (intracranial surgery, extracorporeal circulation);&#xD;
&#xD;
          -  Topic scheduled for obstetrical surgery or outpatient;&#xD;
&#xD;
          -  Subject treated with antipsychotic (neuroleptic or lithium);&#xD;
&#xD;
          -  Subject with cognitive impairment already documented (Alzheimer, dementia,&#xD;
             neurological sequelae);&#xD;
&#xD;
          -  Subject active consumer of narcotics;&#xD;
&#xD;
          -  Subject has not signed informed consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>LOIC MONDOLONI</last_name>
    <role>Study Director</role>
    <affiliation>Assistance Publique Hopitaux De Marseille</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Assistance Publique Hopitaux de Marseille</name>
      <address>
        <city>Marseille</city>
        <zip>13354</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2015</verification_date>
  <study_first_submitted>July 10, 2013</study_first_submitted>
  <study_first_submitted_qc>July 16, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 17, 2013</study_first_posted>
  <last_update_submitted>April 20, 2015</last_update_submitted>
  <last_update_submitted_qc>April 20, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 21, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lorazepam</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

